UroGen Pharma (URGN) Stock Price, News & Analysis

Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Key Stats

• Today's Range: $7.01 to $7.57
• 50-Day Range: $3.93 to $11.64
• 52-Week Range: $3.42 to $20.70
• Volume: 2.67 million shs
• Average Volume: 857,852 shs
• Market Capitalization: $336.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.14
• Consensus Rating: Moderate Buy

UroGen Pharma Stock Analysis - MarketRank™

UroGen Pharma scored higher than 94% of companies evaluated by MarketBeat, and ranked 128th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

UroGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

UroGen Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for UroGen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of UroGen Pharma is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of UroGen Pharma is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.61% of the float of UroGen Pharma has been sold short.

Short Interest Ratio / Days to Cover

UroGen Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in UroGen Pharma has recently decreased by 29.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

UroGen Pharma does not currently pay a dividend.

Dividend Growth

UroGen Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.33

Percentage of Shares Shorted

17.61% of the float of UroGen Pharma has been sold short.

Short Interest Ratio / Days to Cover

UroGen Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in UroGen Pharma has recently decreased by 29.87%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.07

News Sentiment

UroGen Pharma has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 53 news articles for UroGen Pharma this week, compared to 5 articles on an average week.

Search Interest

11 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.

MarketBeat Follows

6 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,044.00 in company stock.

Percentage Held by Insiders

Only 5.10% of the stock of UroGen Pharma is held by insiders.

Percentage Held by Institutions

91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

URGN Stock Analysis - Frequently Asked Questions

How have URGN shares performed this year?

UroGen Pharma's stock was trading at $10.65 at the start of the year. Since then, URGN shares have decreased by 31.5% and is now trading at $7.30.
View the best growth stocks for 2025 here.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by $0.09. The business had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million.
Read the conference call transcript.

When did UroGen Pharma IPO?

UroGen Pharma (URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who are UroGen Pharma's major shareholders?

Top institutional investors of UroGen Pharma include UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (9.46%), RA Capital Management L.P. (6.95%), Vestal Point Capital LP (4.67%) and Nantahala Capital Management LLC (2.96%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith.
View institutional ownership trends.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that UroGen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:URGN
• CIK: 1668243
• Web: www.urogen.com
• Phone: (646) 768-9780
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.14
• High Stock Price Target: $55.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +217.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$102.24 million
• Net Margins: -129.11%
• Pretax Margin: -124.59%
• Return on Equity: N/A
• Return on Assets: -47.94%

Debt

• Debt-to-Equity Ratio: 4.77
• Current Ratio: 9.00
• Quick Ratio: 8.77

Sales & Book Value

• Annual Sales: $91.87 million
• Price / Sales: 3.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.78) per share
• Price / Book: -2.63

Miscellaneous

• Outstanding Shares: 46,107,000
• Free Float: 22,258,000
• Market Cap: $336.58 million
• Optionable: Optionable
• Beta: 0.40